Innoviva (INVA) Interest Expenses (2010 - 2026)
Innoviva's (INVA) quarterly Interest Expenses came in at $26.6 million in Q1 2026, up 1.14% YoY from $26.3 million in Q1 2025, and up 713.7% on a QoQ basis from $3.3 million in Q4 2025.
Analysis
Innoviva (INVA) Interest Expenses (2010 - 2026) Analysis & Trends
Innoviva (INVA) has 17 years of Interest Expenses data on file, last reported at $26.6 million in Q1 2026.
- Quarterly Interest Expenses rose 1.14% year-over-year to $26.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $26.6 million (up 1.14% YoY) and the FY2025 annual result came in at $49.2 million, down 73.78% from the prior year.
- Interest Expenses rose to $26.6 million in Q1 2026, from $3.3 million in the prior quarter.
- In the past five years, Interest Expenses ranged from a high of $187.6 million in Q4 2024 to a low of $3.3 million in Q4 2025.
- A 5-year average of $25.7 million and a median of $15.4 million in 2023 frame the typical range for Interest Expenses.
- Annual changes were most pronounced in 2024 — Interest Expenses soared 5112.08% — and 2025, when it sank 98.26%.
- Tracing INVA's Interest Expenses over 5 years: stood at $5.6 million in 2022, then slumped by 35.43% to $3.6 million in 2023, then soared by 5112.08% to $187.6 million in 2024, then slumped by 98.26% to $3.3 million in 2025, then surged by 713.7% to $26.6 million in 2026.
- The last three Interest Expenses figures came in at $26.6 million (Q1 2026), $3.3 million (Q4 2025), and $13.4 million (Q3 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Interest Expense (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.51 Bn | 130.66 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.24 Bn | 77.25 Bn | 3.93 Bn | 11.00 Mn |
| 3 | Argenx Se | 63.46 Bn | 58.28 Bn | 1.37 Bn | -1.00 Mn |
| 4 | Moderna | 57.89 Bn | 52.75 Bn | 52.00 Mn | - |
| 5 | Revolution Medicines | 44.02 Bn | 44.02 Bn | - | 23.78 Mn |
| 6 | BeOne Medicines | 39.95 Bn | 34.85 Bn | 1.53 Bn | 39.74 Mn |
| 7 | Alnylam Pharmaceuticals | 35.49 Bn | 32.19 Bn | 992.69 Mn | 82.05 Mn |
| 8 | Royalty Pharma | 28.43 Bn | 27.59 Bn | - | 93.62 Mn |
| 9 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 20.27 Mn |
| 10 | Innoviva | 1.56 Bn | 978.20 Mn | 90.62 Mn | 5.47 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 5.47 Mn |
| Mar 31, 2026 | 5.44 Mn |
| Sep 30, 2025 | 13.39 Mn |
| Jun 30, 2025 | 4.66 Mn |
| Mar 31, 2025 | 4.71 Mn |
| Sep 30, 2024 | 17.46 Mn |
| Jun 30, 2024 | 5.80 Mn |
| Mar 31, 2024 | 5.85 Mn |
| Sep 30, 2023 | 13.21 Mn |
| Jun 30, 2023 | 4.38 Mn |
| Mar 31, 2023 | 4.43 Mn |
| Sep 30, 2022 | 11.76 Mn |
| Jun 30, 2022 | 3.66 Mn |
| Mar 31, 2022 | 3.01 Mn |
| Sep 30, 2021 | 14.23 Mn |
| Jun 30, 2021 | 4.75 Mn |
| Mar 31, 2021 | 4.69 Mn |
| Dec 31, 2020 | 4.65 Mn |
| Sep 30, 2020 | 4.60 Mn |
| Jun 30, 2020 | 4.56 Mn |